Praecis drops Plenaxis marketing
Executive Summary
Praecis Pharmaceuticals will continue to make Plenaxis (abarelix) available to existing patients after discontinuing promotional activity for the advanced prostate cancer therapy. The move is part of restructuring plan aimed at reducing cash burn, allowing the company to focus on pipeline products. The company reduced its workforce by 60% to 75 permanent ongoing employees...